From Wikipedia, the free encyclopedia
Content deleted Content added
|
|
Line 7: |
Line 7: |
|
| founder = [[Joseph Schlessinger]] |
|
| founder = [[Joseph Schlessinger]] |
|
| defunct = {{End date and age|2011}} |
|
| defunct = {{End date and age|2011}} |
|
| hq_location = [[Berkeley, California|Berkeley]], [[California]], [[United States]]. |
|
| hq_location = [[South San Francisco, California|South San Francisco]], [[California]], [[United States]]. |
|
}} |
|
}} |
|
|
|
|
|
'''Plexxikon''' is an American [[drug discovery]] company based in [[Berkeley, California]]. It was co-founded in 2001 by [[Joseph Schlessinger]] of [[Yale University]], and [[Sung-Hou Kim]] of the [[University of California, Berkeley]]. |
|
'''Plexxikon''' is an American [[drug discovery]] company based in [[South San Francisco, California]]. It was co-founded in 2001 by [[Joseph Schlessinger]] of [[Yale University]], and [[Sung-Hou Kim]] of the [[University of California, Berkeley]]. |
|
|
|
|
|
It uses a proprietary structural biology-based platform called Scaffold-Based Drug Discovery to build a pipeline of products in multiple therapeutic areas. This discovery process integrates multiple technologies, including structural screening as one key component that it hopes will give a significant competitive advantage over other approaches. |
|
It uses a proprietary structural biology-based platform called Scaffold-Based Drug Discovery to build a pipeline of products in multiple therapeutic areas. This discovery process integrates multiple technologies, including structural screening as one key component that it hopes will give a significant competitive advantage over other approaches. |
Revision as of 17:04, 13 January 2022
Plexxikon is an American drug discovery company based in South San Francisco, California. It was co-founded in 2001 by Joseph Schlessinger of Yale University, and Sung-Hou Kim of the University of California, Berkeley.
It uses a proprietary structural biology-based platform called Scaffold-Based Drug Discovery to build a pipeline of products in multiple therapeutic areas. This discovery process integrates multiple technologies, including structural screening as one key component that it hopes will give a significant competitive advantage over other approaches.
In April 2011, Plexxikon was acquired by the Japanese pharmaceutical company Daiichi Sankyo for $805 million and an additional $130 million in potential milestone payments.[1][2][3]
Daiichi Sankyo announced the shutdown of Plexxikon in 2022.[4]
Drug pipeline
- Plexxikon is collaborating with Wyeth Pharmaceuticals on several products for use in type II diabetes and other metabolic disorders.[5] The most advanced of these agents is indeglitazar (PLX204), which is currently in Phase II clinical trials for type 2 diabetes.[6]
- PLX7486 is a CSF1R antagonist and pan-TRK inhibitor in clinical trials for advanced solid tumors.[7][8]
References